Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2314-8543
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy ; volume:11 ; number:1 ; day:11 ; month:4 ; year:2022 ; pages:1-14 ; date:12.2022
Beni-Suef University Journal of Basic and Applied Sciences / Ǧāmiʿat Banī-Suwaif ; 11, Heft 1 (11.4.2022), 1-14, 12.2022
- Creator
-
Hussain, Amina
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43088-022-00238-8
- URN
-
urn:nbn:de:101:1-2022062621231198563729
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hussain, Amina
- SpringerLink (Online service)
Other Objects (12)
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Generation of macrophages with enhanced functionality using chimeric antigen receptors
Chimeric antigen receptor (CAR)-engineered NK-92 cells : an off-the-shelf cellular therapeutic for universal tumor targeting
Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells
Modular modification of chimeric antigen receptors sheds light on T cell activation
A novel luciferase-based assay for the detection of Chimeric Antigen Receptors
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Generation of macrophages with enhanced functionality using chimeric antigen receptors
Chimeric antigen receptor (CAR)-engineered NK-92 cells : an off-the-shelf cellular therapeutic for universal tumor targeting
Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells
Modular modification of chimeric antigen receptors sheds light on T cell activation
A novel luciferase-based assay for the detection of Chimeric Antigen Receptors
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy
Chimeric antigen receptor engineered natural killer cells for cancer therapy
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Generation of macrophages with enhanced functionality using chimeric antigen receptors
Chimeric antigen receptor (CAR)-engineered NK-92 cells : an off-the-shelf cellular therapeutic for universal tumor targeting
Chimeric antigen receptors: unleashing a new age of anti-cancer therapy
Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells
Modular modification of chimeric antigen receptors sheds light on T cell activation
A novel luciferase-based assay for the detection of Chimeric Antigen Receptors
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies